Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: APOBEC3C

Gene summary for APOBEC3C

Gene summary.

Gene information	Species	Human
	Gene symbol	APOBEC3C
	Gene ID	27350
	Gene name	apolipoprotein B mRNA editing enzyme catalytic subunit 3C
	Gene Alias	A3C
	Cytomap	22q13.1
	Gene Type	protein-coding
	GO ID	GO:0002376
	UniProtAcc	Q9NRW3

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
27350	APOBEC3C	HTA11_2487_2000001011	Human	Colorectum	SER	9.88e-04	1.62e-01	-0.1808
27350	APOBEC3C	HTA11_1938_2000001011	Human	Colorectum	AD	9.49e-04	1.98e-01	-0.0811
27350	APOBEC3C	HTA11_347_2000001011	Human	Colorectum	AD	1.18e-22	4.15e-01	-0.1954
27350	APOBEC3C	HTA11_411_2000001011	Human	Colorectum	SER	4.42e-10	5.69e-01	-0.2602
27350	APOBEC3C	HTA11_3361_2000001011	Human	Colorectum	AD	5.46e-03	2.67e-01	-0.1207
27350	APOBEC3C	HTA11_696_2000001011	Human	Colorectum	AD	2.46e-16	3.75e-01	-0.1464
27350	APOBEC3C	HTA11_866_2000001011	Human	Colorectum	AD	4.46e-07	1.89e-01	-0.1001
27350	APOBEC3C	HTA11_2992_2000001011	Human	Colorectum	SER	2.03e-15	6.42e-01	-0.1706
27350	APOBEC3C	HTA11_5212_2000001011	Human	Colorectum	AD	3.97e-04	2.59e-01	-0.2061
27350	APOBEC3C	HTA11_7862_2000001011	Human	Colorectum	AD	1.24e-02	1.79e-01	-0.0179
27350	APOBEC3C	HTA11_8622_2000001021	Human	Colorectum	SER	8.37e-05	2.47e-01	0.0528
27350	APOBEC3C	HTA11_6818_2000001021	Human	Colorectum	AD	1.15e-02	1.58e-01	0.0588
27350	APOBEC3C	HTA11_99999970781_79442	Human	Colorectum	MSS	9.63e-08	1.74e-01	0.294
27350	APOBEC3C	HTA11_99999965062_69753	Human	Colorectum	MSI-H	1.40e-05	6.32e-01	0.3487
27350	APOBEC3C	HTA11_99999971662_82457	Human	Colorectum	MSS	4.38e-06	1.42e-01	0.3859
27350	APOBEC3C	HTA11_99999974143_84620	Human	Colorectum	MSS	9.10e-25	4.69e-01	0.3005
27350	APOBEC3C	LZE4T	Human	Esophagus	ESCC	1.26e-05	1.79e-01	0.0811
27350	APOBEC3C	LZE8T	Human	Esophagus	ESCC	7.07e-03	1.94e-02	0.067
27350	APOBEC3C	LZE6T	Human	Esophagus	ESCC	7.16e-04	2.86e-01	0.0845
27350	APOBEC3C	P2T-E	Human	Esophagus	ESCC	5.49e-25	1.52e-01	0.1177

Page: 1 2 3 4 5

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0019079110	Oral cavity	LP	viral genome replication	73/4623	131/18723	2.78e-14	3.11e-12	73
GO:0050792110	Oral cavity	LP	regulation of viral process	83/4623	164/18723	6.50e-13	5.74e-11	83
GO:003465518	Oral cavity	LP	nucleobase-containing compound catabolic process	161/4623	407/18723	1.61e-11	1.15e-09	161
GO:001943916	Oral cavity	LP	aromatic compound catabolic process	176/4623	467/18723	1.96e-10	1.08e-08	176
GO:1903900110	Oral cavity	LP	regulation of viral life cycle	72/4623	148/18723	2.23e-10	1.19e-08	72
GO:004427017	Oral cavity	LP	cellular nitrogen compound catabolic process	170/4623	451/18723	3.93e-10	2.02e-08	170
GO:004670016	Oral cavity	LP	heterocycle catabolic process	168/4623	445/18723	4.35e-10	2.20e-08	168
GO:000961516	Oral cavity	LP	response to virus	143/4623	367/18723	7.42e-10	3.52e-08	143
GO:190136116	Oral cavity	LP	organic cyclic compound catabolic process	180/4623	495/18723	3.11e-09	1.35e-07	180
GO:004506918	Oral cavity	LP	regulation of viral genome replication	45/4623	85/18723	2.02e-08	7.41e-07	45
GO:190165711	Oral cavity	LP	glycosyl compound metabolic process	43/4623	88/18723	7.80e-07	2.05e-05	43
GO:004852515	Oral cavity	LP	negative regulation of viral process	43/4623	92/18723	3.47e-06	7.35e-05	43
GO:005160711	Oral cavity	LP	defense response to virus	97/4623	265/18723	9.31e-06	1.74e-04	97
GO:014054611	Oral cavity	LP	defense response to symbiont	97/4623	265/18723	9.31e-06	1.74e-04	97
GO:000911611	Oral cavity	LP	nucleoside metabolic process	31/4623	62/18723	1.46e-05	2.57e-04	31
GO:004507113	Oral cavity	LP	negative regulation of viral genome replication	28/4623	56/18723	3.75e-05	5.55e-04	28
GO:001603229	Skin	cSCC	viral process	211/4864	415/18723	7.04e-28	2.76e-25	211
GO:001905829	Skin	cSCC	viral life cycle	157/4864	317/18723	1.29e-19	1.88e-17	157
GO:0019079112	Skin	cSCC	viral genome replication	76/4864	131/18723	7.80e-15	5.76e-13	76
GO:0034655111	Skin	cSCC	nucleobase-containing compound catabolic process	172/4864	407/18723	4.11e-13	2.43e-11	172

Page: 1 2 3 4 5 6 7

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa05170	Colorectum	AD	Human immunodeficiency virus 1 infection	72/2092	212/8465	1.40e-03	8.46e-03	5.39e-03	72
hsa051701	Colorectum	AD	Human immunodeficiency virus 1 infection	72/2092	212/8465	1.40e-03	8.46e-03	5.39e-03	72
hsa051702	Colorectum	SER	Human immunodeficiency virus 1 infection	58/1580	212/8465	1.08e-03	8.56e-03	6.21e-03	58
hsa051703	Colorectum	SER	Human immunodeficiency virus 1 infection	58/1580	212/8465	1.08e-03	8.56e-03	6.21e-03	58
hsa051704	Colorectum	MSS	Human immunodeficiency virus 1 infection	69/1875	212/8465	2.66e-04	1.98e-03	1.21e-03	69
hsa051705	Colorectum	MSS	Human immunodeficiency virus 1 infection	69/1875	212/8465	2.66e-04	1.98e-03	1.21e-03	69
hsa032509	Esophagus	ESCC	Viral life cycle - HIV-1	54/4205	63/8465	2.01e-09	2.17e-08	1.11e-08	54
hsa05170210	Esophagus	ESCC	Human immunodeficiency virus 1 infection	147/4205	212/8465	3.37e-09	3.53e-08	1.81e-08	147
hsa0325014	Esophagus	ESCC	Viral life cycle - HIV-1	54/4205	63/8465	2.01e-09	2.17e-08	1.11e-08	54
hsa0517038	Esophagus	ESCC	Human immunodeficiency virus 1 infection	147/4205	212/8465	3.37e-09	3.53e-08	1.81e-08	147
hsa0517027	Oral cavity	OSCC	Human immunodeficiency virus 1 infection	133/3704	212/8465	1.42e-08	1.40e-07	7.12e-08	133
hsa032508	Oral cavity	OSCC	Viral life cycle - HIV-1	45/3704	63/8465	7.62e-06	3.59e-05	1.83e-05	45
hsa05170111	Oral cavity	OSCC	Human immunodeficiency virus 1 infection	133/3704	212/8465	1.42e-08	1.40e-07	7.12e-08	133
hsa0325013	Oral cavity	OSCC	Viral life cycle - HIV-1	45/3704	63/8465	7.62e-06	3.59e-05	1.83e-05	45
hsa0517028	Oral cavity	LP	Human immunodeficiency virus 1 infection	92/2418	212/8465	2.18e-06	2.20e-05	1.42e-05	92
hsa0517037	Oral cavity	LP	Human immunodeficiency virus 1 infection	92/2418	212/8465	2.18e-06	2.20e-05	1.42e-05	92

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

APOBEC3C

SNV

Missense_Mutation

rs200673371

c.131G>A

p.Arg44His

p.R44H

Q9NRW3

protein_coding

tolerated(0.93)

benign(0)

TCGA-AQ-A04J-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

APOBEC3C

SNV

Missense_Mutation

c.472N>A

p.Glu158Lys

p.E158K

Q9NRW3

protein_coding

tolerated(0.3)

benign(0.012)

TCGA-D8-A1XT-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin+cyclophosphamide

APOBEC3C

insertion

In_Frame_Ins

novel

c.120_121insATTCTCAGGGCTGTGGAGGGATGGGGGAGGCCCAGAGCCCAG

p.Glu40_Gly41insIleLeuArgAlaValGluGlyTrpGlyArgProArgAlaGln

p.E40_G41insILRAVEGWGRPRAQ

Q9NRW3

protein_coding

TCGA-AN-A04D-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

APOBEC3C

insertion

In_Frame_Ins

novel

c.132_133insATT

p.Arg44_Arg45insIle

p.R44_R45insI

Q9NRW3

protein_coding

TCGA-AQ-A04J-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

APOBEC3C

insertion

Frame_Shift_Ins

novel

c.136_137insGTTTCACATTTTCTTGGTCCACACGGAAC

p.Ser46CysfsTer79

p.S46Cfs*79

Q9NRW3

protein_coding

TCGA-B6-A0IA-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

APOBEC3C

SNV

Missense_Mutation

rs376538641

c.134N>A

p.Arg45His

p.R45H

Q9NRW3

protein_coding

tolerated(0.23)

benign(0.001)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

APOBEC3C

SNV

Missense_Mutation

c.130N>T

p.Arg44Cys

p.R44C

Q9NRW3

protein_coding

tolerated(0.19)

benign(0)

TCGA-EA-A3HS-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

APOBEC3C

SNV

Missense_Mutation

rs756657821

c.160G>A

p.Val54Ile

p.V54I

Q9NRW3

protein_coding

tolerated(0.45)

benign(0.353)

TCGA-EA-A410-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

APOBEC3C

SNV

Missense_Mutation

c.365G>A

p.Arg122His

p.R122H

Q9NRW3

protein_coding

deleterious(0.03)

probably_damaging(0.948)

TCGA-AA-A01R-01

Colorectum

colon adenocarcinoma

Male

<65

III/IV

Chemotherapy

5-fluorouracil

APOBEC3C

SNV

Missense_Mutation

novel

c.403N>T

p.Leu135Phe

p.L135F

Q9NRW3

protein_coding

deleterious(0)

probably_damaging(0.989)

TCGA-AZ-4315-01

Colorectum

colon adenocarcinoma

Male

<65

I/II

Unknown

Page: 1 2 3

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1